Defended Amneal in Hatch-Waxman Litigation Involving Generic Pulmonary Fibrosis Drug
Genentech, Inc. et al v. Amneal Pharmaceuticals LLC, 1:19-cv-00190-RGA and 1:19-cv-00195-RGA (D. Del.)
Robins Kaplan served as lead counsel to Amneal in Hatch-Waxman patent litigation in the U.S. District Court for the District of Delaware brought by Genentech and Intermune asserting infringement of 15 patents covering Esbriet® (pirfenidone) tablets and 19 patents covering Esbriet® (pirfenidone) capsules.
The case began with more than 16 defendant groups and narrowed down to six at the start of expert discovery. Robins Kaplan was among the leaders of the defense group up until the case resolved after a successful mediation that took place in June 2021.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.